0001662579-24-000083.txt : 20240917
0001662579-24-000083.hdr.sgml : 20240917
20240917171236
ACCESSION NUMBER: 0001662579-24-000083
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240916
FILED AS OF DATE: 20240917
DATE AS OF CHANGE: 20240917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boyle Scott N
CENTRAL INDEX KEY: 0001913897
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39567
FILM NUMBER: 241305297
MAIL ADDRESS:
STREET 1: C4 THERAPEUTICS, INC.
STREET 2: 490 ARSENAL WAY, SUITE 200
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: C4 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662579
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 475617627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 231-0700
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
wk-form4_1726607550.xml
FORM 4
X0508
4
2024-09-16
0
0001662579
C4 Therapeutics, Inc.
CCCC
0001913897
Boyle Scott N
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
WATERTOWN
MA
02472
0
1
0
0
Chief Business Officer
0
Common Stock
2024-09-16
4
M
0
2250
A
54580
D
Common Stock
2024-09-16
4
F
0
661
6.36
D
53919
D
Performance Restricted Stock Units
2024-09-16
4
M
0
2250
0
D
2025-02-28
Common Stock
2250
14250
D
Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.
/s/ Jolie M. Siegel, Attorney-in-Fact
2024-09-17